Johnson & Johnson (J&J) announced that they are dropping implementation of a 340B rebate program that would have required 340B entities to purchase certain drugs (Stelara and Xarelto) at the Whole Acquisition Cost and later get the 340B discount. The move is the result of the Health Resources and Services Administration (HRSA) telling J&J that the rebate program violates the 340B statute and failure to terminate the program would result in the Administration referring them to the Office of Inspector General. More than 100 legislators also sent a letter to HHS voicing their opposition to the J&J rebate program, which was previously slated to take effect on October 15^th.